Sign In
Buy MRK
$115.49
+0.320 (+0.278%)
At Close: Jun 17, 2026
Wall Street Analysts Think Merck (MRK) Is a Good Investment: Is It?
10:35am, Wednesday, 02'nd Apr 2025
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employe
Levi & Korsinsky Notifies Merck & Co., Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - MRK
10:15am, Wednesday, 02'nd Apr 2025
NEW YORK, NY / ACCESS Newswire / April 2, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws,
NEW YORK, NY / ACCESS Newswire / April 2, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Merck & Co., Inc. ("Merck" or the "Company") (NYSE:MRK). Such investors are
NEW YORK, NY / ACCESS Newswire / April 2, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws,
MRK Investors Have Final Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit with the Schall Law Firm
09:13am, Wednesday, 02'nd Apr 2025
LOS ANGELES , April 2, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Merck & Co., Inc. ("Merck" or "th
2 Beaten-Down Stocks to Buy and Hold for a Decade
08:15am, Wednesday, 02'nd Apr 2025
Recent market volatility notwithstanding, equities generally deliver solid returns over long periods, like a decade. The key is to purchase shares of robust companies, occasionally adding more, and to
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Merck & Co., Inc. Lawsuit - MRK
07:25am, Wednesday, 02'nd Apr 2025
NEW YORK, NY / ACCESS Newswire / April 2, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws,
NEW YORK, NY / ACCESS Newswire / April 2, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Merck & Co.
Merck & Co., Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - MRK
09:30pm, Tuesday, 01'st Apr 2025
NEW YORK, NY / ACCESS Newswire / April 1, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws,
My Top 10 High-Yield Dividend Stocks For April 2025
08:38pm, Tuesday, 01'st Apr 2025
Q1 2025 ended negatively for SPY and VYM, but my watchlist outperformed, limiting losses to 1.38% and achieving a YTD gain of 1.89%. Since inception, my watchlist has a CAGR of 15.83%, outperforming S
Why Major Pharmaceutical Stocks Tumbled on Tuesday
07:09pm, Tuesday, 01'st Apr 2025
Many investor eyes were on the pharmaceutical industry on Tuesday, and not necessarily for the right reasons. The Trump administration's promised tariffs were set to go into effect the following day,
Levi & Korsinsky Notifies Shareholders of Merck & Co., Inc. (MRK) of a Class Action Lawsuit and an Upcoming Deadline
06:30pm, Tuesday, 01'st Apr 2025
NEW YORK, NY / ACCESS Newswire / April 1, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws,
NEW YORK, NY / ACCESS Newswire / April 1, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws,
NEW YORK CITY, NY / ACCESS Newswire / April 1, 2025 / WHY: New York, N.Y., April 1, 2025.
Trump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocks
02:01pm, Tuesday, 01'st Apr 2025
Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are 'underappreciated.'
